1	The	the	DT	_	3	det	_
2	final	final	JJ	_	3	amod	_
3	proposal	proposal	NN	_	15	nsubj	15:A0;6:A1=PPT
4	,	,	,	_	3	punct	_
5	which	which	WDT	_	6	nsubj	6:R-A1
6	came	come	VBD	pb=come.04	3	rcmod	_
7	within	within	IN	_	6	prep	6:AM-TMP
8	three	#crd#	CD	_	9	num	_
9	days	day	NNS	_	7	pobj	_
10	of	of	IN	_	9	prep	_
11	the	the	DT	_	13	det	_
12	last	last	JJ	_	13	amod	_
13	offer	offer	NN	_	10	pobj	_
14	,	,	,	_	15	punct	_
15	represented	represented	VBD	pb=represent.01	0	root	_
16	a	a	DT	_	19	det	_
17	mark	mark	NN	_	19	hmod	_
18	-	-	HYPH	_	19	hyph	_
19	up	up	NN	_	15	dobj	15:A1
20	of	of	IN	_	19	prep	_
21	around	around	RB	p2=IN	22	advmod	_
22	20	0	CD	_	24	num	_
23	per	per	NN	p2=IN	24	nn	_
24	cent	cent	NN	_	20	pobj	_
25	to	to	IN	_	19	prep	_
26	the	the	DT	_	28	det	_
27	first	#ord#	JJ	_	28	amod	_
28	proposal	proposal	NN	_	25	pobj	29:AM-PRR
29	made	make	VBN	pb=make.05	28	partmod	_
30	in	in	IN	_	29	prep	29:AM-TMP
31	January	january	NNP	_	30	pobj	_
32	this	this	DT	_	33	det	_
33	year	year	NN	_	29	npadvmod	29:AM-TMP
34	.	.	.	_	15	punct	_

1	British	british	JJ	_	3	amod	_
2	drug	drug	NN	_	3	nn	_
3	maker	maker	NN	_	4	nn	_
4	AstraZeneca	astrazeneca	NNP	_	6	nsubj	6:A0=PAG
5	has	have	VBZ	_	6	aux	_
6	rejected	reject	VBN	pb=reject.01	12	ccomp	_
7	the	the	DT	_	11	det	_
8	fourth	#ord#	JJ	_	11	amod	_
9	and	and	CC	_	8	cc	_
10	final	final	JJ	_	8	conj	_
11	takeover	takeover	NN	_	6	dobj	6:A1=PPT
12	offer	offer	VBP	p2=NN|pb=offer.01	0	root	_
13	worth	worth	JJ	_	12	dobj	12:A1=PPT
14	$	$	$	_	16	quantmod	_
15	118	0	CD	_	16	number	_
16	billion	#crd#	CD	_	13	npadvmod	_
17	by	by	IN	_	12	prep	12:A0=PAG
18	Pfizer	pfizer	NNP	_	19	nn	_
19	Inc	inc	NNP	_	17	pobj	_
20	on	on	IN	_	12	prep	12:AM-TMP
21	Monday	monday	NNP	_	20	pobj	_
22	saying	say	VBG	pb=say.01	12	advcl	12:AM-ADV
23	the	the	DT	_	24	det	_
24	offer	offer	NN	_	25	nsubj	27:A0=PAG;25:A1=PPT
25	continues	continue	VBZ	pb=continue.01	22	ccomp	22:A1=PPT
26	to	to	TO	_	27	aux	_
27	have	have	VB	pb=have.03	25	xcomp	25:C-A1
28	a	a	DT	_	31	det	_
29	high	high	JJ	_	31	amod	_
30	stock	stock	NN	_	31	nn	_
31	component	component	NN	_	27	dobj	27:A1=PPT
32	and	and	CC	_	25	cc	_
33	the	the	DT	_	35	det	_
34	overall	overall	JJ	_	35	amod	_
35	proposal	proposal	NN	_	36	nsubj	36:A0=PAG
36	undervalues	undervalue	VBZ	p2=IN|pb=undervalue.01	25	conj	_
37	the	the	DT	_	38	det	_
38	company	company	NN	_	36	dobj	36:A1=PPT
39	.	.	.	_	12	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nsubj	2:A0=PAG
2	offered	offer	VBD	p2=VBN|pb=offer.01	0	root	_
3	AstraZeneca	astrazeneca	NNP	_	4	nn	_
4	shareholders	shareholder	NNS	p2=VBZ	2	iobj	2:A3=GOL
5	1.747	0	CD	_	6	num	_
6	shares	share	NNS	_	2	dobj	2:A1=PPT
7	in	in	IN	_	6	prep	_
8	the	the	DT	_	10	det	_
9	combined	combined	JJ	p2=VBN	10	amod	_
10	entity	entity	NN	_	7	pobj	_
11	and	and	CC	_	6	cc	_
12	2,476	0	CD	_	13	num	_
13	pence	penny	NNS	p2=NN	6	conj	_
14	in	in	IN	_	13	prep	_
15	cash	cash	NN	_	14	pobj	_
16	,	,	,	_	13	punct	_
17	representing	represent	VBG	pb=represent.01	13	partmod	_
18	an	an	DT	_	20	det	_
19	indicative	indicative	JJ	_	20	amod	_
20	value	value	NN	_	17	dobj	17:A1=PPT
21	of	of	IN	_	20	prep	_
22	£55.00	£0	NN	p2=CD	21	pobj	_
23	(	(	-LRB-	_	22	punct	_
24	$	$	$	_	25	nmod	_
25	92.53	0	CD	_	22	appos	_
26	)	)	-RRB-	_	22	punct	_
27	per	per	IN	_	22	prep	_
28	share	share	NN	_	27	pobj	_
29	.	.	.	_	2	punct	_

1	This	this	DT	_	2	nsubj	2:A0=PAG
2	marked	mark	VBD	pb=mark.01	0	root	_
3	a	a	DT	_	7	det	_
4	2.8	0	CD	_	6	num	_
5	per	per	NN	_	6	nn	_
6	cent	cent	NN	_	7	nn	_
7	increase	increase	NN	_	2	dobj	2:A1=PPT
8	compared	compare	VBN	_	7	prep	_
9	with	with	IN	_	8	prep	_
10	the	the	DT	_	12	det	_
11	third	#ord#	JJ	_	12	amod	_
12	proposal	proposal	NN	_	9	pobj	13:A1=PPT
13	made	make	VBN	p2=VBD|pb=make.05	12	partmod	_
14	last	last	JJ	_	15	amod	_
15	week	week	NN	_	13	npadvmod	13:AM-TMP
16	in	in	IN	_	20	prep	20:R-AM-LOC
17	which	which	WDT	_	16	pobj	_
18	Pfizer	pfizer	NNP	_	20	nsubj	20:A0=PAG
19	had	have	VBD	_	20	aux	_
20	offered	offer	VBN	pb=offer.01	2	advcl	_
21	an	an	DT	_	23	det	_
22	indicative	indicative	JJ	_	23	amod	_
23	value	value	NN	_	20	dobj	20:A1=PPT
24	of	of	IN	_	23	prep	_
25	£53.50	£0	CD	p2=PDT	24	pobj	_
26	a	a	DT	_	27	det	_
27	share	share	NN	_	20	dobj	_
28	,	,	,	_	20	punct	_
29	comprising	comprise	VBG	pb=comprise.01	20	advcl	_
30	1.845	0	CD	_	31	num	_
31	shares	share	NNS	_	29	dobj	29:A2
32	in	in	IN	_	31	prep	_
33	the	the	DT	_	35	det	_
34	combined	combined	JJ	p2=VBN	35	amod	_
35	entity	entity	NN	_	32	pobj	_
36	and	and	CC	_	31	cc	_
37	2,157	0	CD	_	38	num	_
38	pence	penny	NNS	p2=NN	31	conj	_
39	per	per	IN	_	38	prep	_
40	AstraZeneca	astrazeneca	NNP	_	41	nn	_
41	share	share	NN	p2=VBP	39	pobj	_
42	.	.	.	_	2	punct	_

1	Last	last	JJ	_	2	amod	_
2	week	week	NN	_	5	npadvmod	5:AM-TMP
3	,	,	,	_	5	punct	_
4	AstraZeneca	astrazeneca	NNP	_	5	nsubj	5:A0=CAU
5	indicated	indicate	VBD	pb=indicate.01	0	root	_
6	that	that	IN	_	9	complm	_
7	its	its	PRP$	_	8	poss	_
8	board	board	NN	_	9	nsubj	9:A0=PAG
9	believes	believe	VBZ	pb=believe.01	5	ccomp	5:A1=PPT
10	that	that	IN	_	16	complm	_
11	Pfizer	pfizer	NNP	_	14	poss	_
12	's	's	POS	_	11	possessive	_
13	£53.50	£0	CD	p2=NN	14	nn	_
14	proposal	proposal	NN	_	16	nsubj	16:A0=PAG
15	substantially	substantially	RB	_	16	advmod	16:AM-MNR
16	undervalues	undervalue	VBZ	p2=IN|pb=undervalue.01	9	ccomp	9:A1=PPT
17	the	the	DT	_	18	det	_
18	company	company	NN	_	16	dobj	16:A1=PPT
19	.	.	.	_	5	punct	_

1	Previously	previously	RB	_	8	advmod	8:AM-TMP
2	,	,	,	_	8	punct	_
3	on	on	IN	_	8	prep	8:AM-TMP
4	May	may	NNP	_	3	pobj	_
5	2	0	CD	_	4	num	_
6	,	,	,	_	8	punct	_
7	Pfizer	pfizer	NNP	_	8	nsubj	8:A0=PAG
8	offered	offer	VBD	pb=offer.01	0	root	_
9	1.845	0	CD	_	10	num	_
10	shares	share	NNS	_	8	dobj	8:A1=PPT
11	of	of	IN	_	10	prep	_
12	the	the	DT	_	14	det	_
13	combined	combine	VBN	p2=JJ|pb=combine.01	14	amod	_
14	entity	entity	NN	_	11	pobj	13:A1=PPT
15	besides	besides	IN	p2=RB	8	prep	8:A3=GOL
16	£15.98	£0	NN	p2=NNS	15	pobj	_
17	in	in	IN	_	16	prep	_
18	cash	cash	NN	_	17	pobj	_
19	for	for	IN	_	18	prep	_
20	each	each	DT	_	21	det	_
21	share	share	NN	_	19	pobj	_
22	of	of	IN	_	21	prep	_
23	AstraZeneca	astrazeneca	NNP	_	22	pobj	_
24	.	.	.	_	8	punct	_

1	The	the	DT	_	2	det	_
2	proposal	proposal	NN	_	3	nsubj	3:A0;13:A0=PAG
3	represented	represented	VBD	pb=represent.01	0	root	_
4	an	an	DT	_	6	det	_
5	indicative	indicative	JJ	_	6	amod	_
6	value	value	NN	_	3	dobj	3:A1
7	of	of	IN	_	6	prep	_
8	£50	£0	NN	p2=CD	7	pobj	_
9	per	per	IN	_	8	prep	_
10	AstraZeneca	astrazeneca	NNP	_	11	nn	_
11	share	share	NN	p2=VBP	9	pobj	_
12	and	and	CC	_	3	cc	_
13	pegged	peg	VBD	pb=peg.01	3	conj	_
14	the	the	DT	_	17	det	_
15	total	total	JJ	_	17	amod	_
16	deal	deal	NN	p2=JJ	17	nn	_
17	value	value	NN	_	13	dobj	13:A1=PPT
18	at	at	IN	_	13	prep	13:A2=PRD
19	$	$	$	_	21	quantmod	_
20	106	0	CD	_	21	number	_
21	billion	#crd#	CD	_	18	pobj	_
22	.	.	.	_	3	punct	_

1	Early	early	RB	_	3	advmod	_
2	this	this	DT	_	3	det	_
3	year	year	NN	_	6	npadvmod	6:AM-TMP
4	Pfizer	pfizer	NNP	_	6	nsubj	6:A0=PAG
5	had	have	VBD	_	6	aux	_
6	offered	offer	VBN	pb=offer.01	0	root	_
7	a	a	DT	_	8	det	_
8	combination	combination	NN	_	6	dobj	6:A1=PPT
9	of	of	IN	_	8	prep	_
10	cash	cash	NN	_	9	pobj	_
11	and	and	CC	_	10	cc	_
12	shares	share	NNS	_	10	conj	_
13	in	in	IN	_	6	prep	_
14	the	the	DT	_	16	det	_
15	combined	combined	JJ	p2=VBN	16	amod	_
16	entity	entity	NN	_	13	pobj	18:A0
17	which	which	WDT	_	18	nsubj	18:R-A0
18	represented	represented	VBD	pb=represent.01	16	rcmod	_
19	an	an	DT	_	21	det	_
20	indicative	indicative	JJ	_	21	amod	_
21	value	value	NN	_	18	dobj	18:A1
22	of	of	IN	_	21	prep	_
23	£46.61	£0	NN	p2=CD	22	pobj	_
24	(	(	-LRB-	_	23	punct	_
25	$	$	$	_	26	nmod	_
26	76.62	0	CD	_	23	appos	_
27	)	)	-RRB-	_	23	punct	_
28	per	per	IN	_	23	prep	_
29	AstraZeneca	astrazeneca	NNP	_	30	nn	_
30	share	share	NN	p2=NNP	28	pobj	_
31	,	,	,	_	58	punct	_
32	a	a	DT	_	33	det	_
33	premium	premium	NN	_	58	nsubjpass	58:A1=PRD
34	of	of	IN	_	33	prep	_
35	approximately	approximately	RB	_	36	advmod	_
36	30	0	CD	_	38	num	_
37	per	per	NN	p2=IN	38	nn	_
38	cent	cent	NN	_	34	pobj	_
39	to	to	IN	p2=TO	33	prep	_
40	AstraZeneca	astrazeneca	NNP	_	44	poss	_
41	's	's	POS	_	40	possessive	_
42	closing	closing	NN	p2=VBG	44	amod	_
43	share	share	NN	_	44	nn	_
44	price	price	NN	_	39	pobj	_
45	on	on	IN	_	33	prep	_
46	January	january	NNP	_	45	pobj	_
47	3	0	CD	_	46	num	_
48	,	,	,	_	46	punct	_
49	2014	0	CD	_	46	appos	_
50	,	,	,	_	46	punct	_
51	a	a	DT	_	52	det	_
52	day	day	NN	_	46	appos	_
53	before	before	IN	_	52	prep	_
54	the	the	DT	_	56	det	_
55	previous	previous	JJ	_	56	amod	_
56	offer	offer	NN	_	53	pobj	_
57	was	be	VBD	_	58	auxpass	_
58	made	make	VBN	pb=make.01	6	advcl	_
59	.	.	.	_	6	punct	_

1	The	the	DT	_	3	det	_
2	new	new	JJ	_	3	amod	_
3	proposal	proposal	NN	_	4	nsubj	4:A0=PAG
4	pushes	push	VBZ	pb=push.01	0	root	_
5	up	up	RP	_	4	prt	4:A2=DIR
6	the	the	DT	_	8	det	_
7	cash	cash	NN	_	8	nn	_
8	component	component	NN	_	4	dobj	4:A1=PPT
9	of	of	IN	_	8	prep	_
10	the	the	DT	_	11	det	_
11	deal	deal	NN	_	9	pobj	_
12	for	for	IN	_	11	prep	_
13	AstraZeneca	astrazeneca	NNP	_	14	nn	_
14	shareholders	shareholder	NNS	_	12	pobj	_
15	,	,	,	_	14	punct	_
16	one	#crd#	CD	_	14	appos	_
17	of	of	IN	_	16	prep	_
18	the	the	DT	_	20	det	_
19	contentious	contentious	JJ	_	20	amod	_
20	issues	issue	NNS	_	17	pobj	_
21	over	over	IN	p2=RB	29	prep	_
22	which	which	WDT	_	21	pobj	_
23	the	the	DT	_	25	det	_
24	British	british	JJ	p2=NNP	25	amod	_
25	drugmaker	drugmaker	NN	p2=NNP	27	poss	_
26	's	's	POS	_	25	possessive	_
27	board	board	NN	_	29	nsubj	29:A0=PAG
28	had	have	VBD	_	29	aux	_
29	rejected	reject	VBN	pb=reject.01	20	rcmod	_
30	the	the	DT	_	32	det	_
31	previous	previous	JJ	_	32	amod	_
32	overtures	overture	NNS	p2=NN	29	dobj	29:A1=PPT
33	.	.	.	_	4	punct	_

1	Relative	relative	JJ	_	12	advcl	12:AM-ADV
2	to	to	IN	_	1	prep	_
3	Pfizer	pfizer	NNP	p2=NN	7	poss	_
4	's	's	POS	_	3	possessive	_
5	May	may	NNP	_	7	nn	_
6	2	0	CD	_	5	num	_
7	proposal	proposal	NN	_	2	pobj	_
8	,	,	,	_	12	punct	_
9	the	the	DT	_	11	det	_
10	final	final	JJ	_	11	amod	_
11	offer	offer	NN	_	12	nsubj	12:A0=PAG
12	marks	mark	VBZ	p2=NNS|pb=mark.01	0	root	_
13	an	an	DT	_	14	det	_
14	increase	increase	NN	_	12	dobj	12:A1=PPT
15	of	of	IN	_	14	prep	_
16	the	the	DT	_	18	det	_
17	cash	cash	NN	_	18	nn	_
18	consideration	consideration	NN	_	15	pobj	_
19	of	of	IN	_	18	prep	_
20	£8.78	£0	NN	p2=CD	19	pobj	_
21	per	per	IN	_	20	prep	_
22	share	share	NN	_	21	pobj	_
23	,	,	,	_	14	punct	_
24	or	or	CC	_	14	cc	_
25	£11.3	£0	CD	p2=IN	26	number	_
26	billion	#crd#	CD	_	14	conj	_
27	;	;	:	p2=,	26	punct	_
28	an	an	DT	_	29	det	_
29	increase	increase	NN	_	26	appos	_
30	in	in	IN	_	29	prep	_
31	the	the	DT	_	33	det	_
32	cash	cash	NN	_	33	nn	_
33	component	component	NN	_	30	pobj	_
34	as	as	IN	_	29	prep	_
35	a	a	DT	_	36	det	_
36	proportion	proportion	NN	_	34	pobj	_
37	of	of	IN	_	36	prep	_
38	the	the	DT	_	40	det	_
39	total	total	JJ	_	40	amod	_
40	consideration	consideration	NN	_	37	pobj	_
41	from	from	IN	_	36	prep	_
42	33	0	CD	_	41	pobj	_
43	per	per	IN	p2=NN	42	prep	_
44	cent	cent	NN	_	43	pobj	_
45	to	to	IN	p2=TO	41	prep	_
46	approximately	approximately	RB	_	47	advmod	_
47	45	0	CD	_	49	num	_
48	per	per	NN	p2=IN	49	nn	_
49	cent	cent	NN	_	45	pobj	_
50	;	;	:	p2=,	29	punct	_
51	a	a	DT	_	53	det	_
52	substantial	substantial	JJ	_	53	amod	_
53	increase	increase	NN	_	45	pobj	_
54	in	in	IN	_	53	prep	_
55	current	current	JJ	_	57	amod	_
56	indicative	indicative	JJ	_	57	amod	_
57	value	value	NN	_	54	pobj	_
58	of	of	IN	_	57	prep	_
59	approximately	approximately	RB	_	60	advmod	_
60	15	0	CD	_	62	num	_
61	per	per	NN	p2=IN	62	nn	_
62	cent	cent	NN	_	58	pobj	_
63	;	;	:	p2=,	53	punct	_
64	and	and	CC	_	53	cc	_
65	an	an	DT	_	67	det	_
66	aggregate	aggregate	JJ	p2=NN	67	amod	_
67	increase	increase	NN	_	53	conj	_
68	in	in	IN	_	67	prep	_
69	the	the	DT	_	73	det	_
70	total	total	JJ	_	73	amod	_
71	current	current	JJ	_	73	amod	_
72	indicative	indicative	JJ	_	73	amod	_
73	value	value	NN	_	68	pobj	_
74	of	of	IN	_	73	prep	_
75	approximately	approximately	RB	_	77	advmod	_
76	£9.1	£0	CD	p2=$	77	number	_
77	billion	#crd#	CD	_	74	pobj	_
78	or	or	CC	_	77	cc	_
79	$	$	$	_	81	quantmod	_
80	15.3	0	CD	_	81	number	_
81	billion	#crd#	CD	_	77	conj	_
82	.	.	.	_	12	punct	_

1	Under	under	IN	_	11	prep	11:AM-LOC
2	the	the	DT	_	4	det	_
3	final	final	JJ	_	4	amod	_
4	proposal	proposal	NN	_	1	pobj	_
5	,	,	,	_	11	punct	_
6	Pfizer	pfizer	NNP	p2=NN	9	nn	_
7	and	and	CC	_	6	cc	_
8	AstraZeneca	astrazeneca	NNP	_	6	conj	_
9	shareholders	shareholder	NNS	_	11	nsubj	11:A0=PAG
10	would	would	MD	_	11	aux	11:AM-MOD
11	own	own	VB	p2=RB|pb=own.01	0	root	_
12	approximately	approximately	RB	_	13	advmod	_
13	74	0	CD	_	15	num	_
14	per	per	NN	p2=IN	15	nn	_
15	cent	cent	NN	_	11	dobj	11:A1=PPT
16	and	and	CC	_	15	cc	_
17	26	0	CD	_	19	num	_
18	per	per	NN	p2=IN	19	nn	_
19	cent	cent	NN	_	15	conj	_
20	,	,	,	_	11	punct	_
21	respectively	respectively	RB	_	11	advmod	11:AM-ADV
22	,	,	,	_	11	punct	_
23	of	of	IN	_	11	prep	_
24	the	the	DT	_	26	det	_
25	combined	combine	VBN	p2=JJ|pb=combine.01	26	amod	_
26	company	company	NN	_	23	pobj	25:A1=PPT
27	.	.	.	_	11	punct	_

1	On	on	IN	_	28	prep	28:AM-ADV
2	the	the	DT	_	3	det	_
3	basis	basis	NN	_	1	pobj	_
4	of	of	IN	_	3	prep	_
5	Pfizer	pfizer	NNP	_	9	poss	_
6	's	's	POS	_	5	possessive	_
7	closing	closing	NN	p2=VBG	9	amod	_
8	share	share	NN	_	9	nn	_
9	price	price	NN	_	4	pobj	_
10	of	of	IN	_	9	prep	_
11	$	$	$	_	12	nmod	_
12	29.12	0	CD	_	10	pobj	_
13	on	on	IN	_	9	prep	_
14	May	may	NNP	_	13	pobj	_
15	16	0	CD	_	14	num	_
16	,	,	,	_	14	punct	_
17	2014	0	CD	_	14	num	_
18	and	and	CC	_	9	cc	_
19	the	the	DT	_	21	det	_
20	exchange	exchange	NN	_	21	nn	_
21	rate	rate	NN	_	9	conj	_
22	on	on	IN	_	21	prep	_
23	that	that	DT	_	24	det	_
24	day	day	NN	_	22	pobj	_
25	,	,	,	_	28	punct	_
26	the	the	DT	_	27	det	_
27	proposal	proposal	NN	_	28	nsubj	28:A0=PAG
28	represents	represent	VBZ	pb=represent.01	0	root	_
29	a	a	DT	_	30	det	_
30	premium	premium	NN	_	28	dobj	28:A1=PPT
31	of	of	IN	_	30	prep	_
32	approximately	approximately	RB	_	33	advmod	_
33	45	0	CD	_	35	num	_
34	per	per	NN	p2=IN	35	nn	_
35	cent	cent	NN	_	31	pobj	_
36	to	to	IN	_	30	prep	_
37	the	the	DT	_	40	det	_
38	unaffected	unaffected	JJ	_	40	amod	_
39	closing	closing	NN	_	40	nn	_
40	price	price	NN	_	36	pobj	_
41	of	of	IN	_	40	prep	_
42	an	an	DT	_	44	det	_
43	AstraZeneca	astrazeneca	NNP	_	44	nn	_
44	share	share	NN	_	41	pobj	_
45	of	of	IN	_	44	prep	_
46	£37.82	£0	NN	p2=NNS	45	pobj	_
47	on	on	IN	_	46	prep	_
48	April	april	NNP	_	47	pobj	_
49	17	0	CD	_	48	num	_
50	,	,	,	_	48	punct	_
51	2014	0	CD	_	48	num	_
52	(	(	-LRB-	_	53	punct	_
53	being	be	VBG	pb=be.01	28	advcl	_
54	the	the	DT	_	55	det	_
55	date	date	NN	_	53	attr	53:A2=PRD
56	before	before	IN	_	55	prep	_
57	market	market	NN	_	58	nn	_
58	speculation	speculation	NN	_	56	pobj	_
59	of	of	IN	_	58	prep	_
60	a	a	DT	_	62	det	_
61	possible	possible	JJ	_	62	amod	_
62	offer	offer	NN	_	59	pobj	_
63	by	by	IN	_	62	prep	_
64	Pfizer	pfizer	NNP	_	63	pobj	_
65	for	for	IN	_	62	prep	_
66	AstraZeneca	astrazeneca	NNP	_	65	pobj	_
67	)	)	-RRB-	_	53	punct	_
68	;	;	:	_	28	punct	_
69	53	0	CD	_	71	num	_
70	per	per	NN	p2=IN	71	nn	_
71	cent	cent	NN	_	88	nsubj	88:A1=PPT
72	to	to	IN	_	71	prep	_
73	the	the	DT	_	75	det	_
74	closing	closing	NN	p2=VBG	75	nn	_
75	price	price	NN	_	72	pobj	_
76	of	of	IN	_	75	prep	_
77	an	an	DT	_	79	det	_
78	AstraZeneca	astrazeneca	NNP	_	79	nn	_
79	share	share	NN	_	76	pobj	_
80	of	of	IN	_	79	prep	_
81	£35.86	£0	NN	p2=CD	80	pobj	_
82	on	on	IN	_	71	prep	_
83	January	january	NNP	_	82	pobj	_
84	3	0	CD	_	83	num	_
85	,	,	,	_	83	punct	_
86	2014	0	CD	_	83	appos	_
87	,	,	,	_	53	punct	_
88	being	be	VBG	pb=be.01	28	advcl	_
89	the	the	DT	_	91	det	_
90	trading	trading	NN	p2=VBG	91	nn	_
91	day	day	NN	p2=RB	88	attr	88:A2=PRD
92	immediately	immediately	RB	_	93	advmod	_
93	prior	prior	RB	_	91	advmod	_
94	to	to	IN	_	93	prep	_
95	the	the	DT	_	96	det	_
96	date	date	NN	_	94	pobj	_
97	of	of	IN	_	96	prep	_
98	Pfizer	pfizer	NNP	_	101	poss	_
99	's	's	POS	_	98	possessive	_
100	January	january	NNP	_	101	nn	_
101	proposal	proposal	NN	_	97	pobj	_
102	;	;	:	_	71	punct	_
103	24	0	CD	_	105	num	_
104	per	per	NN	p2=IN	105	nn	_
105	cent	cent	NN	_	27	appos	_
106	to	to	IN	_	105	prep	_
107	the	the	DT	_	109	det	_
108	current	current	JJ	_	109	amod	_
109	value	value	NN	_	106	pobj	_
110	of	of	IN	_	109	prep	_
111	Pfizer	pfizer	NNP	p2=NN	114	poss	_
112	's	's	POS	_	111	possessive	_
113	January	january	NNP	_	114	nn	_
114	proposal	proposal	NN	_	110	pobj	_
115	;	;	:	_	105	punct	_
116	and	and	CC	_	105	cc	_
117	34	0	CD	_	119	num	_
118	per	per	NN	p2=IN	119	nn	_
119	cent	cent	NN	_	105	conj	_
120	to	to	IN	p2=TO	119	prep	_
121	AstraZeneca	astrazeneca	NNP	_	128	poss	_
122	's	's	POS	p2=VBZ	121	possessive	_
123	all	all	DT	p2=JJ	125	hmod	_
124	-	-	HYPH	_	125	hyph	_
125	time	time	NN	_	128	nn	_
126	high	high	JJ	p2=NN	127	amod	_
127	closing	closing	NN	_	128	nn	_
128	price	price	NN	_	120	pobj	_
129	(	(	-LRB-	_	130	punct	_
130	prior	prior	RB	p2=JJ	91	advmod	_
131	to	to	IN	_	130	prep	_
132	17	0	CD	_	133	num	_
133	April	april	NNP	_	131	pobj	_
134	2014	0	CD	_	133	num	_
135	)	)	-RRB-	_	133	punct	_
136	of	of	IN	_	133	prep	_
137	£41.03	£0	NN	p2=CD	136	pobj	_
138	per	per	IN	_	137	prep	_
139	share	share	NN	_	138	pobj	_
140	since	since	IN	_	137	prep	_
141	the	the	DT	_	142	det	_
142	formation	formation	NN	_	140	pobj	_
143	of	of	IN	_	142	prep	_
144	the	the	DT	_	145	det	_
145	company	company	NN	_	143	pobj	_
146	in	in	IN	_	142	prep	_
147	1999	0	CD	_	146	pobj	_
148	.	.	.	_	28	punct	_

1	He	he	PRP	_	2	nsubj	2:A0=PAG
2	added	add	VBD	pb=add.01	0	root	_
3	that	that	IN	_	13	complm	_
4	following	follow	VBG	_	13	prep	13:AM-TMP
5	a	a	DT	_	6	det	_
6	conversation	conversation	NN	_	4	pobj	_
7	with	with	IN	_	6	prep	_
8	AstraZeneca	astrazeneca	NNP	_	7	pobj	_
9	,	,	,	_	13	punct	_
10	Pfizer	pfizer	NNP	_	13	nsubj	13:A0=PAG
11	does	do	VBZ	_	13	aux	_
12	not	not	RB	_	13	neg	13:AM-NEG
13	believe	believe	VB	pb=believe.01	2	ccomp	2:A1=PPT
14	that	that	IN	_	18	complm	_
15	the	the	DT	_	17	det	_
16	AstraZeneca	astrazeneca	NNP	_	17	nn	_
17	board	board	NN	_	18	nsubj	22:A0=PAG;18:A1=PPT
18	is	be	VBZ	pb=be.01	13	ccomp	13:A1=PPT
19	currently	currently	RB	_	18	advmod	18:AM-TMP
20	prepared	prepared	JJ	p2=VBN	18	acomp	18:A2=PRD
21	to	to	TO	_	22	aux	_
22	recommend	recommend	VB	pb=recommend.01	20	xcomp	_
23	a	a	DT	_	24	det	_
24	deal	deal	NN	_	22	dobj	22:A1=PPT
25	at	at	IN	_	22	prep	22:A3=PRD
26	a	a	DT	_	28	det	_
27	reasonable	reasonable	JJ	_	28	amod	_
28	price	price	NN	_	25	pobj	_
29	.	.	.	_	2	punct	_

1	"	"	``	_	3	punct	_
2	We	we	PRP	_	3	nsubj	6:A0=PAG;3:A1=PPT
3	remain	remain	VBP	pb=remain.01	0	root	_
4	ready	ready	JJ	_	3	acomp	3:A3=PRD
5	to	to	TO	_	6	aux	_
6	engage	engage	VB	pb=engage.01	4	xcomp	_
7	in	in	IN	_	6	prep	6:A2=PPT
8	a	a	DT	_	10	det	_
9	meaningful	meaningful	JJ	_	10	amod	_
10	dialogue	dialogue	NN	_	7	pobj	_
11	but	but	CC	p2=IN	3	cc	_
12	time	time	NN	_	17	nsubj	17:A1=LOC
13	for	for	IN	_	12	prep	_
14	constructive	constructive	JJ	_	15	amod	_
15	engagement	engagement	NN	_	13	pobj	_
16	is	be	VBZ	_	17	aux	_
17	running	run	VBG	pb=run.02	3	conj	_
18	out	out	RP	_	17	prt	17:C-V
19	.	.	.	_	17	punct	_

1	We	we	PRP	_	3	nsubj	3:A0
2	have	have	VBP	_	3	aux	_
3	said	say	VBN	p2=VBD|pb=say.01	0	root	_
4	from	from	IN	_	3	prep	3:AM-TMP
5	the	the	DT	_	6	det	_
6	beginning	beginning	NN	_	4	pobj	_
7	that	that	IN	p2=WDT	10	complm	_
8	we	we	PRP	_	10	nsubj	10:A1=PPT;11:A1=PPT
9	will	will	MD	_	10	aux	10:AM-MOD;11:AM-MOD
10	remain	remain	VB	pb=remain.01	3	ccomp	3:A1=PPT
11	disciplined	discipline	VBN	p2=JJ|pb=discipline.01	10	acomp	10:A3=PRD
12	in	in	IN	_	10	prep	10:AM-TMP
13	the	the	DT	_	14	det	_
14	price	price	NN	_	12	pobj	_
15	we	we	PRP	_	16	nsubj	19:A0=PAG;16:A1=PPT
16	are	be	VBP	pb=be.01	14	rcmod	_
17	willing	willing	JJ	_	16	acomp	16:A2=PRD
18	to	to	TO	_	19	aux	_
19	pay	pay	VB	pb=pay.01	17	xcomp	_
20	and	and	CC	_	10	cc	_
21	we	we	PRP	_	24	nsubj	24:A0
22	will	will	MD	_	24	aux	24:AM-MOD
23	not	not	RB	_	24	neg	24:AM-NEG
24	depart	depart	VB	pb=depart.01	10	conj	_
25	from	from	IN	_	24	prep	24:A2=GOL
26	that	that	DT	p2=IN	28	det	_
27	guiding	guide	VBG	pb=guide.01	28	amod	_
28	principle	principle	NN	_	25	pobj	27:A0=PAG
29	.	.	.	_	3	punct	_

1	We	we	PRP	_	2	nsubj	2:A0=PAG
2	believe	believe	VBP	pb=believe.01	31	ccomp	31:A1=PPT
3	that	that	IN	_	6	complm	_
4	our	our	PRP$	_	5	poss	_
5	proposal	proposal	NN	_	6	nsubj	6:A0=PAG
6	represents	represent	VBZ	pb=represent.01	2	ccomp	2:A1=PPT
7	compelling	compelling	JJ	_	10	amod	_
8	and	and	CC	_	7	cc	_
9	full	full	JJ	_	7	conj	_
10	value	value	NN	_	6	dobj	6:A1=PPT
11	for	for	IN	_	10	prep	_
12	AstraZeneca	astrazeneca	NNP	p2=NN	11	pobj	_
13	and	and	CC	_	6	cc	_
14	that	that	IN	p2=WDT	25	mark	_
15	other	other	JJ	_	16	amod	_
16	issues	issue	NNS	_	25	nsubj	25:A0=PAG;20:A1=PPT
17	that	that	WDT	_	20	nsubjpass	20:R-A1
18	have	have	VBP	_	20	aux	_
19	been	be	VBN	_	20	auxpass	_
20	raised	raise	VBN	pb=raise.01	16	rcmod	_
21	by	by	IN	_	20	agent	20:A0=PAG
22	AstraZeneca	astrazeneca	NNP	_	21	pobj	_
23	do	do	VBP	_	25	aux	_
24	not	not	RB	_	25	neg	25:AM-NEG
25	represent	represent	VB	pb=represent.01	6	conj	_
26	material	material	NN	p2=JJ	27	nn	_
27	difficulties	difficulty	NNS	_	25	dobj	25:A1=PPT
28	,	,	,	_	31	punct	_
29	"	"	''	_	31	punct	_
30	he	he	PRP	_	31	nsubj	31:A0=PAG
31	added	add	VBD	pb=add.01	0	root	_
32	.	.	.	_	31	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nsubj	2:A0=PAG;18:A0=PAG
2	confirms	confirm	VBZ	pb=confirm.01	0	root	_
3	that	that	IN	_	7	complm	_
4	it	it	PRP	_	7	nsubj	7:A0=PAG
5	will	will	MD	_	7	aux	7:AM-MOD
6	not	not	RB	_	7	neg	7:AM-NEG
7	make	make	VB	pb=make.05	2	ccomp	2:A1=PPT
8	a	a	DT	_	10	det	_
9	hostile	hostile	JJ	_	10	amod	_
10	offer	offer	NN	_	7	dobj	7:AM-PRR
11	directly	directly	RB	_	7	advmod	7:AM-MNR
12	to	to	IN	p2=TO	7	prep	7:A2=DIR
13	AstraZeneca	astrazeneca	NNP	_	14	nn	_
14	shareholders	shareholder	NNS	_	12	pobj	_
15	and	and	CC	_	2	cc	_
16	will	will	MD	_	18	aux	18:AM-MOD
17	only	only	RB	_	18	advmod	18:AM-ADV
18	announce	announce	VB	pb=announce.01	2	conj	_
19	a	a	DT	_	21	det	_
20	firm	firm	JJ	p2=NN	21	amod	_
21	intention	intention	NN	_	18	dobj	18:A1=PPT
22	to	to	TO	_	23	aux	_
23	make	make	VB	pb=make.LV	21	infmod	_
24	an	an	DT	_	25	det	_
25	offer	offer	NN	_	23	dobj	23:AM-PRR
26	with	with	IN	_	25	prep	_
27	the	the	DT	_	28	det	_
28	recommendation	recommendation	NN	_	26	pobj	_
29	of	of	IN	_	28	prep	_
30	the	the	DT	_	31	det	_
31	board	board	NN	_	29	pobj	_
32	of	of	IN	_	31	prep	_
33	directors	director	NNS	_	32	pobj	_
34	of	of	IN	_	33	prep	_
35	AstraZeneca	astrazeneca	NNP	_	34	pobj	_
36	.	.	.	_	2	punct	_

1	Leif	leif	NNP	p2=IN	2	nn	_
2	Johansson	johansson	NNP	_	8	nsubj	8:A0;10:A0=PAG
3	,	,	,	_	2	punct	_
4	chairman	chairman	NN	_	2	appos	_
5	of	of	IN	_	4	prep	_
6	AstraZeneca	astrazeneca	NNP	_	5	pobj	_
7	,	,	,	_	2	punct	_
8	said	say	VBD	pb=say.01	0	root	_
9	even	even	RB	_	10	advmod	10:AM-ADV
10	assuming	assume	VBG	pb=assume.02	8	advcl	8:AM-ADV
11	that	that	IN	p2=DT	19	complm	_
12	other	other	JJ	_	14	amod	_
13	key	key	JJ	_	14	amod	_
14	aspects	aspect	NNS	_	19	nsubj	19:A1=PPT
15	of	of	IN	_	14	prep	_
16	any	any	DT	_	17	det	_
17	proposal	proposal	NN	_	15	pobj	_
18	had	have	VBD	_	19	aux	_
19	been	be	VBN	pb=be.01	10	ccomp	10:A1=PPT
20	satisfactory	satisfactory	JJ	_	19	acomp	19:A2=PRD
21	,	,	,	_	38	punct	_
22	the	the	DT	_	23	det	_
23	price	price	NN	_	38	nsubj	40:A1=PPT;31:AM-LOC
24	at	at	IN	_	31	prep	31:R-AM-LOC
25	which	which	WDT	_	24	pobj	_
26	the	the	DT	_	27	det	_
27	company	company	NN	_	29	poss	_
28	's	's	POS	_	27	possessive	_
29	board	board	NN	_	31	nsubj	34:A0=PAG;31:A1=PPT
30	would	would	MD	_	31	aux	31:AM-MOD
31	be	be	VB	pb=be.01	23	rcmod	_
32	prepared	prepared	JJ	p2=VBN	31	acomp	31:A2=PRD
33	to	to	TO	_	34	aux	_
34	provide	provide	VB	pb=provide.01	32	xcomp	_
35	a	a	DT	_	36	det	_
36	recommendation	recommendation	NN	_	34	dobj	34:A1=PPT
37	would	would	MD	_	38	aux	38:AM-MOD
38	have	have	VB	pb=have.02	8	ccomp	8:A1=PPT
39	to	to	TO	_	40	aux	_
40	be	be	VB	pb=be.01	38	xcomp	_
41	more	more	JJR	_	43	amod	_
42	than	than	IN	_	43	quantmod	_
43	10	0	CD	_	45	num	_
44	per	per	NN	p2=IN	45	nn	_
45	cent	cent	NN	_	40	attr	40:A2=PRD
46	(	(	-LRB-	_	45	punct	_
47	over	over	IN	p2=RP	45	prep	_
48	£58.85	£0	CD	p2=-RRB-	47	pobj	_
49	a	a	DT	_	50	det	_
50	share	share	NN	_	48	npadvmod	_
51	as	as	IN	p2=RB	45	prep	_
52	against	against	IN	_	51	prep	_
53	£55	£0	CD	p2=-LRB-	52	pobj	_
54	a	a	DT	_	55	det	_
55	share	share	NN	_	53	npadvmod	_
56	in	in	IN	_	45	prep	_
57	the	the	DT	_	59	det	_
58	final	final	JJ	_	59	amod	_
59	offer	offer	NN	_	56	pobj	_
60	)	)	-RRB-	_	40	punct	_
61	above	above	IN	_	40	prep	_
62	Pfizer	pfizer	NNP	_	65	poss	_
63	's	's	POS	_	62	possessive	_
64	Friday	friday	NNP	_	65	nn	_
65	proposal	proposal	NN	_	61	pobj	_
66	.	.	.	_	8	punct	_

1	"	"	``	_	28	punct	_
2	The	the	DT	_	4	det	_
3	final	final	JJ	_	4	amod	_
4	proposal	proposal	NN	_	5	nsubj	5:A1=PPT
5	is	be	VBZ	pb=be.01	28	ccomp	28:A1=PPT
6	a	a	DT	_	8	det	_
7	minor	minor	JJ	_	8	amod	_
8	improvement	improvement	NN	_	5	attr	10:A0;12:A1=PPT;24:A1=PPT;5:A2=PRD
9	which	which	WDT	_	10	nsubj	10:R-A0;12:R-A1;24:R-A1
10	continues	continue	VBZ	pb=continue.01	8	rcmod	_
11	to	to	TO	_	12	aux	_
12	fall	fall	VB	pb=fall.01	10	xcomp	10:A1=PPT
13	short	short	RB	p2=JJ	12	advmod	12:A4=GOL
14	of	of	IN	_	13	prep	_
15	the	the	DT	_	16	det	_
16	board	board	NN	_	18	poss	_
17	's	's	POS	_	16	possessive	_
18	view	view	NN	_	14	pobj	_
19	of	of	IN	_	18	prep	_
20	value	value	NN	_	19	pobj	_
21	and	and	CC	_	10	cc	_
22	has	have	VBZ	_	24	aux	_
23	been	be	VBN	_	24	auxpass	_
24	rejected	reject	VBN	pb=reject.01	10	conj	_
25	,	,	,	_	28	punct	_
26	"	"	''	_	28	punct	_
27	he	he	PRP	_	28	nsubj	28:A0=PAG
28	added	add	VBD	pb=add.01	0	root	_
29	.	.	.	_	28	punct	_

1	He	he	PRP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	Pfizer	pfizer	NNP	_	5	nsubj	7:A0=PAG;5:A1=PAG
4	has	have	VBZ	_	5	aux	_
5	failed	fail	VBN	pb=fail.01	2	ccomp	2:A1=PPT
6	to	to	TO	_	7	aux	_
7	make	make	VB	pb=make.02	5	xcomp	5:A2=PPT
8	a	a	DT	_	15	det	_
9	compelling	compelling	JJ	_	15	amod	_
10	strategic	strategic	JJ	_	15	amod	_
11	,	,	,	_	10	punct	_
12	business	business	NN	_	15	nn	_
13	or	or	CC	_	12	cc	_
14	value	value	NN	_	12	conj	_
15	case	case	NN	_	7	dobj	7:A1=PRD
16	.	.	.	_	2	punct	_

1	"	"	``	_	15	punct	_
2	As	as	IN	_	15	prep	15:AM-ADV
3	an	an	DT	_	5	det	_
4	independent	independent	JJ	p2=NN	5	amod	_
5	company	company	NN	_	2	pobj	_
6	,	,	,	_	15	punct	_
7	the	the	DT	_	9	det	_
8	entire	entire	JJ	_	9	amod	_
9	value	value	NN	_	15	nsubj	15:A1=PPT
10	of	of	IN	_	9	prep	_
11	AstraZeneca	astrazeneca	NNP	_	13	poss	_
12	's	's	POS	_	11	possessive	_
13	pipeline	pipeline	NN	_	10	pobj	_
14	will	will	MD	_	15	aux	15:AM-MOD
15	accrue	accrue	VB	pb=accrue.01	0	root	_
16	to	to	IN	_	15	prep	_
17	our	our	PRP$	_	18	poss	_
18	shareholders	shareholder	NNS	_	16	pobj	_
19	.	.	.	_	15	punct	_

1	Under	under	IN	_	11	prep	11:AM-LOC
2	Pfizer	pfizer	NNP	_	5	poss	_
3	's	's	POS	_	2	possessive	_
4	final	final	JJ	_	5	amod	_
5	proposal	proposal	NN	_	1	pobj	_
6	this	this	DT	_	7	det	_
7	value	value	NN	_	11	nsubjpass	11:A1=PPT
8	would	would	MD	_	11	aux	11:AM-MOD
9	be	be	VB	_	11	auxpass	_
10	significantly	significantly	RB	_	11	advmod	11:AM-MNR
11	diluted	dilute	VBN	pb=dilute.01	15	ccomp	15:A1=PPT
12	,	,	,	_	15	punct	_
13	"	"	''	p2=``	15	punct	_
14	Johansson	johansson	NNP	_	15	nsubj	15:A0
15	said	say	VBD	pb=say.01	0	root	_
16	.	.	.	_	15	punct	_

1	"	"	``	_	49	punct	_
2	We	we	PRP	_	4	nsubj	4:A0=PAG
3	have	have	VBP	_	4	aux	_
4	rejected	reject	VBN	pb=reject.01	49	ccomp	49:A1=PPT
5	Pfizer	pfizer	NNP	_	8	poss	_
6	's	's	POS	_	5	possessive	_
7	final	final	JJ	_	8	amod	_
8	proposal	proposal	NN	_	4	dobj	4:A1=PPT
9	because	because	IN	_	11	mark	_
10	it	it	PRP	_	11	nsubj	15:A0=PAG;11:A1=PPT
11	is	be	VBZ	pb=be.01	4	advcl	4:AM-CAU
12	inadequate	inadequate	JJ	_	11	acomp	11:A2=PRD
13	and	and	CC	_	11	cc	_
14	would	would	MD	_	15	aux	15:AM-MOD
15	present	present	VB	p2=JJ|pb=present.01	11	conj	_
16	significant	significant	JJ	_	17	amod	_
17	risks	risk	NNS	_	15	dobj	15:A1=PPT
18	for	for	IN	_	17	prep	_
19	shareholders	shareholder	NNS	_	18	pobj	_
20	,	,	,	_	15	punct	_
21	while	while	IN	_	23	mark	_
22	also	also	RB	_	23	advmod	_
23	having	have	VBG	pb=have.03	15	advcl	_
24	serious	serious	JJ	_	25	amod	_
25	consequences	consequence	NNS	_	23	dobj	23:A1=PPT
26	for	for	IN	_	25	prep	_
27	the	the	DT	_	28	det	_
28	company	company	NN	_	26	pobj	_
29	,	,	,	_	28	punct	_
30	our	our	PRP$	_	31	poss	_
31	employees	employee	NNS	_	28	conj	_
32	and	and	CC	_	31	cc	_
33	the	the	DT	_	37	det	_
34	life	life	NN	_	36	hmod	_
35	-	-	HYPH	_	36	hyph	_
36	sciences	science	NNS	_	37	nn	_
37	sector	sector	NN	_	31	conj	_
38	in	in	IN	_	37	prep	_
39	the	the	DT	_	40	det	_
40	UK	uk	NNP	_	38	pobj	_
41	,	,	,	_	40	punct	_
42	Sweden	sweden	NNP	_	40	conj	_
43	and	and	CC	_	42	cc	_
44	the	the	DT	_	45	det	_
45	US	us	NNP	_	42	conj	_
46	,	,	,	_	49	punct	_
47	"	"	''	p2=``	49	punct	_
48	he	he	PRP	_	49	nsubj	49:A0=PAG
49	added	add	VBD	pb=add.01	0	root	_
50	.	.	.	_	49	punct	_

1	AstraZeneca	astrazeneca	NNP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	the	the	DT	_	4	det	_
4	majority	majority	NN	_	12	nsubj	12:A1=PPT;14:A1=PPT
5	of	of	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	consideration	consideration	NN	_	5	pobj	_
8	in	in	IN	_	4	prep	_
9	the	the	DT	_	11	det	_
10	final	final	JJ	_	11	amod	_
11	offer	offer	NN	_	8	pobj	_
12	continues	continue	VBZ	pb=continue.01	2	ccomp	2:A1=PPT
13	to	to	TO	_	14	aux	_
14	be	be	VB	pb=be.01	12	xcomp	12:C-A1
15	in	in	IN	_	14	prep	14:A2=PRD
16	Pfizer	pfizer	NNP	_	17	nn	_
17	shares	share	NNS	_	15	pobj	26:A1=PPT
18	which	which	WDT	_	26	dobj	26:R-A1
19	many	many	JJ	_	21	amod	_
20	AstraZeneca	astrazeneca	NNP	p2=JJ	21	nn	_
21	shareholders	shareholder	NNS	_	24	nsubjpass	26:A0=PAG;24:A1=PPT
22	will	will	MD	_	24	aux	24:AM-MOD
23	be	be	VB	_	24	auxpass	_
24	forced	force	VBN	pb=force.01	17	rcmod	_
25	to	to	TO	_	26	aux	_
26	sell	sell	VB	pb=sell.01	24	xcomp	24:A2=PRD
27	.	.	.	_	2	punct	_

1	Further	far	RB	_	15	advmod	15:AM-DIS
2	,	,	,	_	15	punct	_
3	for	for	IN	_	15	prep	15:AM-ADV
4	those	those	DT	_	6	det	_
5	AstraZeneca	astrazeneca	NNP	p2=JJ	6	nn	_
6	shareholders	shareholder	NNS	_	3	pobj	9:A0=PAG
7	able	able	JJ	_	6	amod	_
8	to	to	TO	_	9	aux	_
9	hold	hold	VB	pb=hold.01	7	xcomp	_
10	Pfizer	pfizer	NNP	p2=NN	11	nn	_
11	shares	share	NNS	_	9	dobj	9:A1=PPT
12	,	,	,	_	15	punct	_
13	the	the	DT	_	14	det	_
14	board	board	NN	_	15	nsubj	15:A0=PAG
15	believes	believe	VBZ	pb=believe.01	0	root	_
16	Pfizer	pfizer	NNP	_	18	poss	_
17	's	's	POS	_	16	possessive	_
18	proposals	proposal	NNS	_	21	nsubj	21:A0=PAG;26:A0=PAG
19	would	would	MD	_	21	aux	21:AM-MOD;26:AM-MOD
20	materially	materially	RB	_	21	advmod	21:AM-MNR
21	alter	alter	VB	pb=alter.01	15	ccomp	15:A1=PPT
22	the	the	DT	_	24	det	_
23	investment	investment	NN	_	24	nn	_
24	case	case	NN	_	21	dobj	21:A1=PPT
25	and	and	CC	_	21	cc	_
26	create	create	VB	p2=VBP|pb=create.01	21	conj	_
27	risks	risk	NNS	_	26	dobj	26:A1=PPT
28	and	and	CC	_	27	cc	_
29	uncertainties	uncertainty	NNS	_	27	conj	_
30	.	.	.	_	15	punct	_

1	In	in	IN	_	4	prep	4:AM-DIS
2	particular	particular	JJ	_	1	amod	_
3	it	it	PRP	_	4	nsubj	4:A0=PAG
4	pointed	point	VBD	pb=point.02	0	root	_
5	out	out	RP	_	4	prt	4:C-V
6	the	the	DT	_	7	det	_
7	risks	risk	NNS	_	4	dobj	4:A1=PPT;8:A1=PPT
8	associated	associate	VBN	pb=associate.01	7	partmod	_
9	with	with	IN	_	8	prep	8:A2=PPT
10	delivery	delivery	NN	_	9	pobj	_
11	of	of	IN	_	10	prep	_
12	cost	cost	NN	_	13	nn	_
13	reductions	reduction	NNS	_	11	pobj	_
14	and	and	CC	_	4	cc	_
15	imply	imply	VB	p2=VBP|pb=imply.01	4	conj	_
16	a	a	DT	_	18	det	_
17	meaningful	meaningful	JJ	_	18	amod	_
18	reduction	reduction	NN	_	15	dobj	15:A1=PPT
19	in	in	IN	_	18	prep	_
20	research	research	NN	_	19	pobj	_
21	and	and	CC	_	20	cc	_
22	development	development	NN	_	20	conj	_
23	potential	potential	NN	p2=JJ	20	conj	_
24	and	and	CC	_	23	cc	_
25	capabilities	capability	NNS	_	23	conj	_
26	;	;	:	p2=,	29	punct	_
27	integration	integration	NN	_	29	nsubj	29:A0=PAG
28	would	would	MD	_	29	aux	29:AM-MOD
29	risk	risk	VB	pb=risk.01	59	ccomp	_
30	significant	significant	JJ	_	31	amod	_
31	disruption	disruption	NN	_	29	dobj	29:A1=PPT
32	to	to	IN	_	29	prep	29:AM-ADV
33	the	the	DT	_	34	det	_
34	delivery	delivery	NN	_	32	pobj	_
35	and	and	CC	_	34	cc	_
36	value	value	NN	_	34	conj	_
37	of	of	IN	_	34	prep	_
38	AstraZeneca	astrazeneca	NNP	_	40	poss	_
39	's	's	POS	_	38	possessive	_
40	pipeline	pipeline	NN	_	37	pobj	_
41	;	;	:	_	59	punct	_
42	Pfizer	pfizer	NNP	_	46	poss	_
43	's	's	POS	_	42	possessive	_
44	announced	announce	VBN	p2=JJ|pb=announce.01	46	amod	_
45	business	business	NN	_	46	nn	_
46	segmentation	segmentation	NN	_	59	nsubj	59:A0=PAG;44:A1=PPT
47	,	,	,	_	59	punct	_
48	if	if	IN	_	51	mark	_
49	it	it	PRP	_	51	nsubjpass	51:A1=PPT
50	were	be	VBD	_	51	auxpass	_
51	applied	apply	VBN	pb=apply.02	59	advcl	59:AM-ADV
52	to	to	IN	_	51	prep	51:A2=PRD
53	AstraZeneca	astrazeneca	NNP	_	55	poss	_
54	's	's	POS	_	53	possessive	_
55	business	business	NN	_	52	pobj	_
56	,	,	,	_	59	punct	_
57	would	would	MD	_	59	aux	59:AM-MOD
58	likely	likely	RB	_	59	advmod	59:AM-ADV
59	lead	lead	VB	pb=lead.03	4	ccomp	_
60	to	to	IN	_	59	prep	59:A2=PRD
61	value	value	NN	_	62	nn	_
62	destruction	destruction	NN	_	60	pobj	_
63	and	and	CC	_	59	cc	_
64	also	also	RB	_	65	advmod	65:AM-DIS
65	noted	note	VBD	pb=note.01	59	conj	_
66	that	that	IN	_	73	complm	_
67	the	the	DT	_	72	det	_
68	tax	tax	NN	_	70	hmod	_
69	-	-	HYPH	_	70	hyph	_
70	driven	drive	VBN	_	72	amod	_
71	inversion	inversion	NN	_	72	nn	_
72	structure	structure	NN	_	73	nsubj	73:A1=PPT
73	remains	remain	VBZ	pb=remain.01	65	ccomp	65:A1=PPT
74	a	a	DT	_	76	det	_
75	key	key	JJ	_	76	amod	_
76	part	part	NN	_	73	attr	73:A3=PRD
77	of	of	IN	_	76	prep	_
78	Pfizer	pfizer	NNP	_	80	poss	_
79	's	's	POS	_	78	possessive	_
80	proposals	proposal	NNS	_	77	pobj	_
81	.	.	.	_	4	punct	_

1	The	the	DT	_	3	det	_
2	inversion	inversion	NN	p2=JJ	3	nn	_
3	structure	structure	NN	_	6	nsubj	6:A1=PPT
4	has	have	VBZ	_	6	aux	_
5	already	already	RB	_	6	advmod	6:AM-TMP
6	been	be	VBN	pb=be.01	0	root	_
7	the	the	DT	_	8	det	_
8	subject	subject	NN	_	6	attr	6:A2=PRD
9	of	of	IN	_	8	prep	_
10	intense	intense	JJ	_	14	amod	_
11	public	public	JJ	p2=NN	14	amod	_
12	and	and	CC	_	11	cc	_
13	governmental	governmental	JJ	_	11	conj	_
14	scrutiny	scrutiny	NN	_	9	pobj	_
15	,	,	,	_	6	punct	_
16	particularly	particularly	RB	_	17	advmod	_
17	in	in	IN	_	6	prep	_
18	the	the	DT	_	19	det	_
19	US	us	NNP	_	17	pobj	_
20	,	,	,	_	6	punct	_
21	as	as	IN	_	6	prep	6:AM-CAU
22	a	a	DT	_	23	det	_
23	result	result	NN	_	21	pobj	_
24	of	of	IN	_	23	prep	_
25	Pfizer	pfizer	NNP	p2=NN	28	poss	_
26	's	's	POS	_	25	possessive	_
27	possible	possible	JJ	_	28	amod	_
28	offer	offer	NN	_	24	pobj	_
29	for	for	IN	_	28	prep	_
30	AstraZeneca	astrazeneca	NNP	_	29	pobj	_
31	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	board	board	NN	_	3	nsubj	3:A0
3	said	say	VBD	pb=say.01	0	root	_
4	it	it	PRP	_	5	nsubj	5:A0=PAG
5	believes	believe	VBZ	pb=believe.01	3	ccomp	3:A1=PPT
6	this	this	DT	_	7	det	_
7	structure	structure	NN	_	8	nsubj	8:A0=PAG
8	brings	bring	VBZ	pb=bring.01	5	ccomp	5:A1=PPT
9	increased	increase	VBN	pb=increase.01	10	amod	_
10	uncertainty	uncertainty	NN	_	8	dobj	8:A1=PPT;9:A1=PPT
11	as	as	IN	_	12	mark	_
12	regards	regard	VBZ	p2=NNS|pb=regard.01	8	advcl	8:AM-ADV
13	the	the	DT	_	14	det	_
14	delivery	delivery	NN	_	12	dobj	12:A1
15	of	of	IN	_	14	prep	_
16	value	value	NN	_	15	pobj	_
17	for	for	IN	_	16	prep	_
18	AstraZeneca	astrazeneca	NNP	_	19	nn	_
19	shareholders	shareholder	NNS	_	17	pobj	_
20	.	.	.	_	3	punct	_

1	Web	web	NN	_	2	nn	_
2	page	page	NN	_	3	nn	_
3	addresses	address	NNS	_	7	nsubj	7:A1=PPT
4	and	and	CC	_	3	cc	_
5	e-mail	e-mail	NN	_	6	nn	_
6	addresses	address	NNS	_	3	conj	_
7	turn	turn	VBP	pb=turn.01	0	root	_
8	into	into	IN	_	7	prep	7:AM-DIR
9	links	link	NNS	_	8	pobj	_
10	automatically	automatically	RB	_	7	advmod	7:AM-DIR
11	.	.	.	_	7	punct	_

1	Web	web	NN	_	2	nn	_
2	page	page	NN	_	3	nn	_
3	addresses	address	NNS	_	7	nsubj	7:A1=PPT
4	and	and	CC	_	3	cc	_
5	e-mail	e-mail	NN	_	6	nn	_
6	addresses	address	NNS	_	3	conj	_
7	turn	turn	VBP	pb=turn.01	0	root	_
8	into	into	IN	_	7	prep	7:AM-DIR
9	links	link	NNS	_	8	pobj	_
10	automatically	automatically	RB	_	7	advmod	7:AM-DIR
11	.	.	.	_	7	punct	_

1	Lines	line	NNS	p2=NNP	4	nsubj	4:A0=PAG
2	and	and	CC	_	1	cc	_
3	paragraphs	paragraph	NNS	_	1	conj	_
4	break	break	VBP	pb=break.01	0	root	_
5	automatically	automatically	RB	_	4	advmod	4:AM-MNR
6	.	.	.	_	4	punct	_

1	Web	web	NN	_	2	nn	_
2	page	page	NN	_	3	nn	_
3	addresses	address	NNS	_	7	nsubj	7:A1=PPT
4	and	and	CC	_	3	cc	_
5	e-mail	e-mail	NN	_	6	nn	_
6	addresses	address	NNS	_	3	conj	_
7	turn	turn	VBP	pb=turn.01	0	root	_
8	into	into	IN	_	7	prep	7:AM-DIR
9	links	link	NNS	_	8	pobj	_
10	automatically	automatically	RB	_	7	advmod	7:AM-DIR
11	.	.	.	_	7	punct	_

1	Enter	enter	VB	pb=enter.01	0	root	_
2	the	the	DT	_	3	det	_
3	characters	character	NNS	_	1	dobj	1:A1=LOC;4:A1=PPT
4	shown	show	VBN	pb=show.01	3	partmod	_
5	in	in	IN	_	4	prep	4:AM-LOC
6	the	the	DT	_	7	det	_
7	image	image	NN	_	5	pobj	_
8	.	.	.	_	1	punct	_

1	A	a	DT	_	2	det	_
2	property	property	NN	_	0	root	_
3	of	of	IN	_	2	prep	_
4	Mosaic	mosaic	NNP	_	8	nn	_
5	Media	media	NNP	_	8	nn	_
6	Ventures	venture	NNPS	p2=NNP	8	nn	_
7	Pvt	pvt	NNP	p2=NNPS	8	nn	_
8	Ltd.	ltd.	NNP	_	3	pobj	_

